PIKFYVE and non-Hodgkin lymphoma: Furthermore, the PIKfyve inhibitor Apilimod has been used in several phase I clinical trials for the treatment of Crohn's disease, non-Hodgkin lymphoma, and more recently in the prevention of COVID-19 (clinicaltrials.com, alternative names: STA-5326 and LAM-002).